Therefore, we hypothesized that combination treatment with OBP-702 would improve the antitumor efficacy of Ad-p53 DC vaccine therapy by activating p53 immunogenicity in tumor cells and tumor-infiltration of CTLs, resulting in enhancement of the antitumor immune response. The gene discussed is TP53; the disease is neoplasm.